Anaplastic thyroid cancer (ATC) is an aggressive subtype of thyroid cancer, accounting for 1 to 2% of all cases. Deregulations of cell cycle regulatory genes including cyclins, cyclin-dependent kinases (CDKs), and endogenous inhibitors of CDKs (CKIs) are hallmarks of cancer cells and hence, studies indicate the inhibition of CDK4/6 kinases and cell cycle progression as potent therapeutic strategies. In this study, we investigated the anti-tumor activity of Abemaciclib, a CDK4 and CDK6 inhibitor, in ATC cell lines

 

 

 

Elaheh S Abutorabi # 1 2, Arash Poursheikhani # 3, Bahareh Kashani # 1, Sahar Shamsaiegahkani 1, Vahid Haghpanah 4, Davood Bashash 5, Seied A Mousavi 1, Majid Momeny 6,

Seyed H Ghaffari 7author: 

 

 

DOI: 10.1007/s11033-023-08255-1